WuXi’s New Unit Joins Race For Drug Innovation In China
This article was originally published in The Pink Sheet Daily
Executive Summary
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.
You may also be interested in...
CEO Podcast: Hengrui's US Subsidiary's CEO, CMO On Chinese Pharma Going Global
While many pharma firms in China choose to partner with US companies, Jiangsu Hengrui is relying on itself to go global. The Chinese pharma giant is betting on its newly established US subsidiary Luzsana in a major move to make its wide-ranging products more available, accessible and affordable to patients in the US and the rest of the world.
China's mRNA Shot Shows Benefits Over Older COVID Vaccines
Home-grown Chinese mRNA COVID-19 vaccines are more effective than domestic inactivated virus-based shots, new trial results show.
Shanghai Reopens, Beijing Offers Policy Relief As Pharma Embraces Uncertain Future
China’s largest commercial center and pharma industry hub reopens after over two months of strict lockdown.